{"log_id": 1013225861096478706, "direction": 0, "words_result_num": 44, "words_result": [{"probability": {"variance": 0.000797, "average": 0.990293, "min": 0.827927}, "location": {"width": 820, "top": 212, "height": 27, "left": 222}, "words": "7.肝毒性药物与磺胺药合用,可能引起肝毒性发生率的增高。对此类患者尤其是用药时间较"}, {"probability": {"variance": 3.8e-05, "average": 0.995706, "min": 0.978307}, "location": {"width": 311, "top": 244, "height": 25, "left": 226}, "words": "长及以往有肝病史者应监测肝功能"}, {"probability": {"variance": 0.00188, "average": 0.985054, "min": 0.791075}, "location": {"width": 456, "top": 274, "height": 27, "left": 221}, "words": "8.光敏药物与磺胺药合用可能发生光敏的相加作用"}, {"probability": {"variance": 0.000331, "average": 0.99301, "min": 0.91335}, "location": {"width": 412, "top": 306, "height": 26, "left": 223}, "words": "9.接受磺胺药治疗者对维生素K的需要量增加"}, {"probability": {"variance": 0.00262, "average": 0.989922, "min": 0.663374}, "location": {"width": 824, "top": 338, "height": 28, "left": 223}, "words": "10.乌洛托品在酸性尿中可分解产生甲醛,后者可与磺胺形成不溶性沉淀物,使发生结晶尿的"}, {"probability": {"variance": 0.000142, "average": 0.995968, "min": 0.9531}, "location": {"width": 293, "top": 370, "height": 26, "left": 222}, "words": "危险性增加,因此不宜两药合用"}, {"probability": {"variance": 0.003165, "average": 0.983105, "min": 0.668619}, "location": {"width": 726, "top": 399, "height": 29, "left": 223}, "words": "11.磺胺药可取代保泰松的血浆蛋白结合部位,当两者合用时可增强保泰松的作用"}, {"probability": {"variance": 0.001069, "average": 0.973199, "min": 0.899139}, "location": {"width": 155, "top": 434, "height": 23, "left": 225}, "words": "12.磺吡酮( sulfi"}, {"probability": {"variance": 5.2e-05, "average": 0.995809, "min": 0.972468}, "location": {"width": 569, "top": 433, "height": 27, "left": 476}, "words": ")与磺胺类药物合用时可减少后者自肾小管的分泌,其血药浓度"}, {"probability": {"variance": 9.3e-05, "average": 0.996451, "min": 0.941021}, "location": {"width": 822, "top": 463, "height": 27, "left": 220}, "words": "升高且持久,从而产生毒性,因此在应用磺吡酮期间或在应用其治疗后可能需要调整磺胺药"}, {"probability": {"variance": 5.2e-05, "average": 0.99653, "min": 0.964071}, "location": {"width": 820, "top": 495, "height": 29, "left": 221}, "words": "的剂量。当磺吡酮疗程较长时,对磺胺药的血药浓度宜进行监测,有助于剂量的调整,保证"}, {"probability": {"variance": 0, "average": 0.99948, "min": 0.998859}, "location": {"width": 85, "top": 527, "height": 25, "left": 221}, "words": "安全用药"}, {"probability": {"variance": 0.000394, "average": 0.992565, "min": 0.907577}, "location": {"width": 821, "top": 559, "height": 28, "left": 223}, "words": "3.与洋地黄类或叶酸合用时,后者吸收减少,血药浓度降低,因此须随时观察洋地黄类的作"}, {"probability": {"variance": 0, "average": 0.999704, "min": 0.999303}, "location": {"width": 85, "top": 590, "height": 26, "left": 219}, "words": "用和疗效"}, {"probability": {"variance": 0.001139, "average": 0.991839, "min": 0.780953}, "location": {"width": 811, "top": 622, "height": 28, "left": 222}, "words": "4.与丙磺舒合用,会降低肾小管磺胺排泌量,致磺胺的血药浓度上升,作用延长,容易中毒"}, {"probability": {"variance": 0.000102, "average": 0.994421, "min": 0.950991}, "location": {"width": 768, "top": 655, "height": 25, "left": 219}, "words": "15.与新霉素合用,新霉素抑制肠道菌群,影响柳氮磺吡啶在肠道内分解,使作用降低"}, {"probability": {"variance": 4.8e-05, "average": 0.996792, "min": 0.969174}, "location": {"width": 820, "top": 685, "height": 27, "left": 223}, "words": "【药物过量】当每天用量达到或超过4g或血清药物浓度超过50g/ml,不良反应或毒性反应"}, {"probability": {"variance": 0.000118, "average": 0.996945, "min": 0.930312}, "location": {"width": 821, "top": 717, "height": 28, "left": 216}, "words": "增多。过量时多出现恶心和呕吐症状。对于过量的处理,首先应洗胃,采用活性碳治疗,继"}, {"probability": {"variance": 0.000949, "average": 0.991746, "min": 0.814625}, "location": {"width": 819, "top": 749, "height": 27, "left": 218}, "words": "而静脉补液利尿,静脉给予碳酸氢钠碱化处理,警惕出现少尿和无尿症状,若发生无尿,应"}, {"probability": {"variance": 0.012264, "average": 0.968925, "min": 0.465993}, "location": {"width": 827, "top": 781, "height": 27, "left": 217}, "words": "及时进行透析治疗。若出现高铁血红蛋白症(出现紫绀)时,应静脉缓慢给予变甲兰(美兰)"}, {"probability": {"variance": 0.000408, "average": 0.989198, "min": 0.910077}, "location": {"width": 813, "top": 811, "height": 29, "left": 215}, "words": "每公斤体重1~2mg或其他合适治疗,若有严重的硫血红蛋白血症时,则可进行输血替换治疗"}, {"probability": {"variance": 1e-06, "average": 0.998078, "min": 0.997027}, "location": {"width": 112, "top": 844, "height": 25, "left": 222}, "words": "【药理毒理】"}, {"probability": {"variance": 7e-06, "average": 0.997595, "min": 0.993268}, "location": {"width": 85, "top": 874, "height": 24, "left": 215}, "words": "药理作用"}, {"probability": {"variance": 0.002563, "average": 0.981371, "min": 0.761783}, "location": {"width": 785, "top": 906, "height": 29, "left": 249}, "words": "柳氮磺吡啶及其代谢产物5-氨基水杨酸和磺胺嘧啶的作用方式尚不明确,可能与其在动"}, {"probability": {"variance": 0.000605, "average": 0.992618, "min": 0.849401}, "location": {"width": 822, "top": 938, "height": 27, "left": 213}, "words": "物和体外试验中表现出的抗炎和免疫调节作用有关,动物放射自显影研究表明柳氮磺吡啶"}, {"probability": {"variance": 0.012529, "average": 0.970405, "min": 0.435032}, "location": {"width": 811, "top": 969, "height": 28, "left": 230}, "words": "S)能与结缔组织亲和,并在浆液、肝脏和肠壁中处于相对较高的水平。对溃疡性结肠炎"}, {"probability": {"variance": 0.015255, "average": 0.937519, "min": 0.503157}, "location": {"width": 823, "top": 1001, "height": 29, "left": 213}, "words": "患者分别直肠给子柳氮磺吡啶及其主要代谢物5-氨基水杨酸和磺胺吡啶的临床研究表明,产"}, {"probability": {"variance": 0.007177, "average": 0.982996, "min": 0.44904}, "location": {"width": 825, "top": 1032, "height": 26, "left": 213}, "words": "生主要治疗作用的可能是5-氨基水杨酸。柳氮磺吡啶主要通过柳氮磺吡啶原药还是其主要代"}, {"probability": {"variance": 0, "average": 0.999451, "min": 0.998802}, "location": {"width": 312, "top": 1064, "height": 24, "left": 212}, "words": "谢产物产生抗风湿性作用尚不明确"}, {"probability": {"variance": 1e-06, "average": 0.99837, "min": 0.997419}, "location": {"width": 83, "top": 1095, "height": 23, "left": 212}, "words": "毒理研究"}, {"probability": {"variance": 0.000109, "average": 0.995093, "min": 0.935392}, "location": {"width": 824, "top": 1125, "height": 27, "left": 210}, "words": "遗传毒性:在Ames试验及L51784小鼠淋巴瘤细胞 HGPRT基因试验中SSZ均为表现出致突变"}, {"probability": {"variance": 0.005392, "average": 0.985076, "min": 0.522046}, "location": {"width": 822, "top": 1156, "height": 28, "left": 211}, "words": "作用。但在大鼠、小鼠骨髓微核试验及小鼠外周RBC试验、姐妹染色体互换试验、染色体崎"}, {"probability": {"variance": 0.011304, "average": 0.976799, "min": 0.44537}, "location": {"width": 569, "top": 1189, "height": 26, "left": 157}, "words": "3变试验及人淋巴细胞微核试验中,其致突变作用尚不明确"}, {"probability": {"variance": 0.000777, "average": 0.992176, "min": 0.806835}, "location": {"width": 823, "top": 1220, "height": 29, "left": 210}, "words": "生殖毒性:雄性大鼠给药量为800mg/kg/日(4800mg/m2)时,出现雄性生育力损害,临床上"}, {"probability": {"variance": 0.001571, "average": 0.99163, "min": 0.745295}, "location": {"width": 823, "top": 1254, "height": 27, "left": 211}, "words": "有柳氮磺吡啶给药引起精子减少症和不育的报道,停药后可自行恢复,大鼠及家兔给药剂量"}, {"probability": {"variance": 6.2e-05, "average": 0.996736, "min": 0.951407}, "location": {"width": 822, "top": 1284, "height": 27, "left": 210}, "words": "达人用量的6倍时,雌性动物生育力和胎仔未出现明显损害,目前尚无充分和严格控制的孕"}, {"probability": {"variance": 3.6e-05, "average": 0.996158, "min": 0.981133}, "location": {"width": 210, "top": 1317, "height": 27, "left": 208}, "words": "妇用药的临床研究资料"}, {"probability": {"variance": 0.001429, "average": 0.98498, "min": 0.78377}, "location": {"width": 822, "top": 1348, "height": 28, "left": 208}, "words": "致癌性:进行了F34/N大鼠和B6C3F1小鼠经口给药两年的致癌性研究,大鼠给药量分别为"}, {"probability": {"variance": 0.000205, "average": 0.993161, "min": 0.906102}, "location": {"width": 824, "top": 1381, "height": 26, "left": 209}, "words": "84mg/kg/日(496mg/m2)、168mg/kg/日和337.5mg/kg/日,结果雄性大鼠尿道膀胱移行细胞"}, {"probability": {"variance": 0.000265, "average": 0.993822, "min": 0.892579}, "location": {"width": 811, "top": 1412, "height": 27, "left": 208}, "words": "乳头瘤的发生率升高(统计学有显著意义),雌性大鼠337.5mg/kg/日剂量组有2例4%"}, {"probability": {"variance": 0.001767, "average": 0.989475, "min": 0.741305}, "location": {"width": 848, "top": 1439, "height": 33, "left": 207}, "words": "出现肾脏移行细胞乳头瘤;大鼠尿道膀胱和肾脏肿瘤发生率的增加与肾结石的形成和移行细"}, {"probability": {"variance": 0.001548, "average": 0.98353, "min": 0.77998}, "location": {"width": 809, "top": 1474, "height": 28, "left": 207}, "words": "胞上皮的增生有关。小鼠给药量分别为675mg/kg/日(2025mg/m2)、1350mg/kg/日和2700mg/k"}, {"probability": {"variance": 0.000335, "average": 0.994754, "min": 0.895434}, "location": {"width": 637, "top": 1507, "height": 26, "left": 209}, "words": "日时,各给药组雌、雄小鼠肝细胞腺瘤、癌的发生率均明显高于对照组"}, {"probability": {"variance": 2e-06, "average": 0.998869, "min": 0.99547}, "location": {"width": 132, "top": 1539, "height": 24, "left": 213}, "words": "【药代动力学】"}], "language": 3}